Jennifer McKie Adams - 17 Jun 2026 Form 4 Insider Report for Eton Pharmaceuticals, Inc. (ETON)

Reporting relationship: Director
Issuer ticker: ETON
Reported as of: 17 Jun 2026
Net transaction value: -$1,623,795
SEC form: 4
Accepted by SEC: 17 Jun 2026, 17:08:00 UTC
Prior SEC filing: 14 Jan 2026
Next SEC filing: 04 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Judith Matthews

Key filing fact

Jennifer McKie Adams filed Form 4 for Eton Pharmaceuticals, Inc. (ETON) on 17 Jun 2026.

Key facts

This page summarizes Jennifer McKie Adams's Form 4 filing for Eton Pharmaceuticals, Inc. (ETON).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Jun 2026, 17:08.

Change

Previous filing in this sequence was filed on 14 Jan 2026.
Current net transaction value: -$1,623,795.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001851440 Primary reporting owner

Adams Jennifer McKie

Relationship: Director
Address: C/O ETON PHARMACEUTICALS, INC., 21925 W. FIELD PARKWAY, SUITE 235, DEERPARK
Signature: /s/ Judith Matthews
Signature date: 17 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ETON transaction

Common Stock

Options Exercise

Transaction value
Shares: +50,000
Change %
Price: $3.78^*
Shares after: 50,000
Date: 17 Jun 2026
Ownership: Direct

ETON transaction

Common Stock

Sale

Transaction value: $1,623,795
Shares: -50,000
Change %: -100%
Price: $32.48
Shares after: 0
Date: 17 Jun 2026
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ETON transaction Derivative

Employee Stock Option

Options Exercise

Transaction value
Shares: -50,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 17 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $3.78
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F2

The shares subject to the option vested on a quarterly basis over 12 months from the date of grant until fully vested on February 7, 2023.

Footnote F3

The shares were sold in multiple trades at prices ranging from $32.10 to $32.71. The price reported above reflects the weighted average sales price.

SEC remarks

The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.